Identification of Chagas disease biomarkers using untargeted metabolomics
Herreros-Cabello, Alfonso (Universidad Autónoma de Madrid (UAM). Departamento de Biología Molecular)
Bosch-Nicolau, Pau (Universitat Autònoma de Barcelona. Departament de Medicina)
Pérez-Molina, José A. (Hospital Universitario Ramón y Cajal (Madrid))
Salvador Velez, Fernando Maria (Universitat Autònoma de Barcelona. Departament de Medicina)
Monge-Maillo, Begoña (Hospital Universitario Ramón y Cajal (Madrid))
Rodríguez Palomares, José F. (Instituto de Salud Carlos III)
Ribeiro, Antonio Luiz Pinho (Universidade Federal de Minas Gerais)
Sánchez-Montalvá, Adrián (Universitat Autònoma de Barcelona. Departament de Medicina)
Sabino, Ester Cerdeira (Universidade de São Paulo)
Norman, Francesca F. (Hospital Universitario Ramón y Cajal (Madrid))
Fresno, Manuel (Hospital Universitario de la Princesa (Madrid))
Gironès, Núria (Hospital Universitario de la Princesa (Madrid))
Molina Romero, Israel (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2024
Resum:	Untargeted metabolomic analysis is a powerful tool used for the discovery of novel biomarkers. Chagas disease (CD), caused by Trypanosoma cruzi, is a neglected tropical disease that affects 6-7 million people with approximately 30% developing cardiac manifestations. The most significant clinical challenge lies in its long latency period after acute infection, and the lack of surrogate markers to predict disease progression or cure. In this cross-sectional study, we analyzed sera from 120 individuals divided into four groups: 31 indeterminate CD, 41 chronic chagasic cardiomyopathy (CCC), 18 Latin Americans with other cardiomyopathies and 30 healthy volunteers. Using a high-throughput panel of 986 metabolites, we identified three distinct profiles among individuals with cardiomyopathy, indeterminate CD and healthy volunteers. After a more stringent analysis, we identified some potential biomarkers. Among peptides, phenylacetylglutamine and fibrinopeptide B (1-13) exhibited an increasing trend from controls to ICD and CCC. Conversely, reduced levels of bilirubin and biliverdin alongside elevated urobilin correlated with disease progression. Finally, elevated levels of cystathionine, phenol glucuronide and vanillactate among amino acids distinguished CCC individuals from ICD and controls. Our novel exploratory study using metabolomics identified potential biomarker candidates, either alone or in combination that if confirmed, can be translated into clinical practice.
Ajuts:	Proyectos de investigación en salud, Instituto Carlos III, Ministry of Science, Innovation and Universities, Spanish Government PI19/01807
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Chagas disease ; Untargeted metabolomics ; Biomarkers ; Chronic chagasic cardiomyopathy ; Prognosis
Publicat a:	Scientific reports, Vol. 14 (august 2024) , ISSN 2045-2322

DOI: 10.1038/s41598-024-69205-w
PMID: 39138245

11 p, 2.3 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats